Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 28Multiple Myeloma 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Hodgkin Disease 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Lymphoma, Non-Hodgkin 10Lymphoma 10Hematologic Neoplasms 10Neuroblastoma 9Myeloproliferative Disorders 9Anemia, Refractory, with Excess of Blasts 8Lymphoma, Mantle-Cell 7Leukemia, Myelomonocytic, Chronic 7Leukemia 7Neoplasms, Plasma Cell 6Lymphoma, T-Cell 6Leukemia, Biphenotypic, Acute 6Graft vs Host Disease 6Leukemia, Lymphocytic, Chronic, B-Cell 5Burkitt Lymphoma 5Recurrence 4Primary Myelofibrosis 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Leukemia, Myelomonocytic, Juvenile 4Hematologic Diseases 4Ganglioneuroblastoma 4Anemia, Aplastic 4

Interventions

venetoclax 1fludarabine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Venentoclax × Melphalan × 1 year × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡